Sangamo Therapeutics Files to Sell Mixed Securities

Sangamo Therapeutics shares were barely changed Tuesday after the company registered with the Securities and Exchange Commission to sell up to $200 million in shares, debt securities and/or warrants.

Sangamo said it will use proceeds for general corporate purposes, including support for its research and development, pre-clinical and clinical trial activities, commercialization activities, business development activities, and, if opportunities arise, acquisitions of businesses, products, technologies or licenses that are complementary to its business. It noted that it has currently no plans for acquisitions.